Form 4: Xenon Pharmaceuticals Director Steven Gannon Boosts Stake with Significant Equity Grants

Xenon Pharmaceuticals Inc. Director Steven Gannon has increased his beneficial ownership through the acquisition of stock options and restricted share units, aligning his interests with long-term shareholder value.

Summary

• Steven Gannon, a Director of Xenon Pharmaceuticals Inc. (XENE), reported transactions on June 5, 2025.
• He disposed of 3 common shares at a price of $30.48 per share, which were automatically sold to cover a transfer fee for moving shares to an alternate brokerage account.
• Following this minor disposition, Gannon directly beneficially owns 7,141 common shares.
• Gannon acquired 17,012 share options with an exercise price of $30.73 per share, which vest 100% on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting of shareholders, and expire on June 4, 2035.
• He also acquired 2,645 Restricted Share Units (RSUs), each representing a contingent right to receive one common share, vesting 100% on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting of shareholders.

Sentiment

Score: 8

Explanation: The sentiment is positive as a director is significantly increasing their equity stake through compensation grants, aligning their interests with shareholders. The minor share disposition is administrative and does not detract from the overall positive signal.

Positives

• Director Steven Gannon's acquisition of 17,012 stock options and 2,645 Restricted Share Units demonstrates a significant increase in his equity stake, aligning his financial interests with the long-term performance and share price appreciation of Xenon Pharmaceuticals.
• The vesting schedule for both options and RSUs, tied to future dates (June 4, 2026, or the 2026 annual meeting), indicates a commitment to the company's future success.

Negatives

• A minor disposition of 3 common shares occurred, but this was for an administrative purpose (payment of a transfer fee) and does not reflect a negative sentiment towards the company.

Future Outlook

The acquisition of stock options and restricted share units by a director, with vesting scheduled for mid-2026, indicates a forward-looking compensation strategy designed to incentivize long-term performance and align management interests with future shareholder returns.

Industry Context

The grant of equity compensation, such as stock options and restricted share units, to directors is a standard practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors like Xenon Pharmaceuticals. This mechanism is widely used to attract, retain, and incentivize key personnel by linking their compensation directly to the company's stock performance and long-term success.

Comparison to Industry Standards

• The structure of equity compensation, including stock options and restricted share units with multi-year vesting, is consistent with common practices observed in the biotechnology and pharmaceutical industries for director compensation. Companies such as Biogen Inc. (BIIB), Gilead Sciences, Inc. (GILD), and Amgen Inc. (AMGN) frequently utilize similar equity-based incentives to align director and executive interests with shareholder value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: The increased equity ownership by a director through compensation grants is generally positive, as it aligns the director's financial incentives with the company's stock performance, potentially leading to more shareholder-friendly decisions and long-term value creation.

Next Steps

• Vesting of 17,012 share options on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting of shareholders.
• Vesting of 2,645 Restricted Share Units on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting of shareholders.

Key Dates

Recommendation

Keywords

Xenon Pharmaceuticals, XENE, Form 4, Insider Transaction, Stock Options, Restricted Share Units, Director Compensation, Equity Grant, Beneficial Ownership